Compare SAFE & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SAFE | ARDX |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 842.7M | 862.3M |
| IPO Year | 1999 | 2014 |
| Metric | SAFE | ARDX |
|---|---|---|
| Price | $12.01 | $3.11 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | ★ $17.60 | $12.90 |
| AVG Volume (30 Days) | 621.7K | ★ 4.1M |
| Earning Date | 11-04-2026 | 10-29-2026 |
| Dividend Yield | ★ 5.87% | N/A |
| EPS Growth | ★ 7.43 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $385,552,000.00 | $2,607,000.00 |
| Revenue This Year | $12.09 | $19.98 |
| Revenue Next Year | $4.69 | $27.70 |
| P/E Ratio | $14.71 | ★ N/A |
| Revenue Growth | ★ 5.43 | N/A |
| 52 Week Low | $11.60 | $3.18 |
| 52 Week High | $17.45 | $8.40 |
| Indicator | SAFE | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 29.47 | 26.15 |
| Support Level | $11.60 | N/A |
| Resistance Level | $16.43 | $3.63 |
| Average True Range (ATR) | 0.30 | 0.10 |
| MACD | 0.08 | 0.01 |
| Stochastic Oscillator | 33.07 | 8.33 |
Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.